Business
Pulmatrix Reports Q2 2020 Results and Business Updates
Strategic Partner Sensory Cloud Advancing Toward Commercial Launch of FEND in Fall 2020 as OTC Nasal Hygiene Product for COVID-19 Received MHRA approval of
About this update from Pulmatrix, Inc.
[{"type":"text","content":"Strategic Partner Sensory Cloud Advancing Toward Commercial Launch of FEND in Fall 2020 as OTC Nasal Hygiene Product for COVID-19\n Received MHRA approval of the PUR1800 Ph1b clinical trial, enabling a study start in 2H 2020\n Strengthened balance sheet with gross proceeds from a registered direct offering in April and a warrant exercise transaction in July\n\n\nLEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its Q2 2020 financial results and provides a business update.\n\n \n \n \n \n \n \n\n \n\"The second quarter has been marked with important progress for our strategic partnership with Sensory Cloud,\" said Ted Raad, Chief Executive Officer of Pulmatrix. \"The recent publication of data demonstrating the ability of FEND to suppress the exhalation of respiratory droplets, which can transmit airborne infections, leaves us confident that our proprietary NasoCalm technology can be applied to provide an important new OTC hygiene option for addressing the spread of COVID-19. We look forward to an anticipated commercial launch in the fall of this year and believe the royalty stream from the commercialization of FEND, upon the commencement of sales, could be an important source of non-dilutive funding to fuel our internal development pipeline.\" \nMr. Raad continued, \"Together with our partner Cipla, we decided to end our Phase 2 clinical study of Pulmazole for the treatment of asthma patients with ABPA. We are leveraging this pause in our development program to prepare for a new Phase 2b study of longer study duration and inclusion of efficacy endpoints that are intended to better inform and propel the program forward. While we prepare for a potential study start in 3Q 2021, we are working with Cipla to amend the Phase 2 development and commercialization agreement to include the new Phase 2b development plan and budget. In our partnership with Johnson & Johnson, we achieved a significant milestone with the MRHA approval of the PUR1800 Ph1b study, enabling us to start the study in 2H 2020.\"\nQ2 and Recent Highlights:\nAnnounced partner Sensory Cloud's progress towards the commercialization of FEND, an over the c...